| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
535,387 |
438,344 |
$51.96M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
595,953 |
486,819 |
$33.41M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
588,109 |
303,996 |
$9.67M |
| 87581 |
|
548,173 |
447,673 |
$8.61M |
| 87507 |
|
65,787 |
59,890 |
$6.75M |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
484,167 |
391,939 |
$6.44M |
| 87631 |
|
97,610 |
84,816 |
$3.92M |
| 87486 |
|
196,560 |
163,990 |
$3.84M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
290,994 |
246,769 |
$3.16M |
| 87481 |
|
162,150 |
70,459 |
$3.05M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
194,075 |
170,988 |
$2.46M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
195,812 |
172,531 |
$2.42M |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
187,167 |
164,522 |
$2.09M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
65,941 |
55,202 |
$1.62M |
| 87511 |
|
145,471 |
125,906 |
$1.45M |
| 87529 |
|
103,316 |
46,715 |
$1.15M |
| 87641 |
|
96,612 |
77,761 |
$1.05M |
| 87541 |
|
84,164 |
67,523 |
$984K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
6,516 |
5,255 |
$246K |
| 87500 |
|
19,307 |
16,352 |
$240K |
| 87632 |
|
4,614 |
3,813 |
$189K |
| 87563 |
|
16,044 |
13,362 |
$132K |
| 87505 |
|
3,447 |
3,336 |
$82K |
| 87634 |
|
8,081 |
7,470 |
$68K |
| 87501 |
|
6,956 |
6,438 |
$63K |
| 87498 |
|
3,603 |
3,059 |
$38K |
| 87532 |
|
1,319 |
1,093 |
$13K |
| 87799 |
|
324 |
301 |
$10K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,043 |
3,420 |
$10K |
| 87653 |
|
978 |
887 |
$8K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
274 |
251 |
$4K |
| 87493 |
|
210 |
183 |
$3K |
| 87186 |
|
718 |
649 |
$2K |
| 87088 |
|
718 |
649 |
$2K |
| 99499 |
|
39 |
38 |
$0.00 |